COMPARISON OF MOLECULAR AND CONVENTIONAL STRATEGIES FOR FOLLOWUP OF SUPERFICIAL BLADDER CANCER USING DECISION ANALYSIS
Authors:
- 1 March 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 163 (3) , 752-757
Abstract
Patients with superficial bladder cancer require long-term surveillance for recurrence. We compared the cost of cystoscopy and cytology (standard care) to that of urinary markers (modified care) for patients with a history of superficial bladder cancer. We constructed a decision analysis model that compared the 2 strategies for a hypothetical followup interval of 3 years. Probabilities required for the decision tree were based on a cohort of 361 patients diagnosed with superficial bladder cancer from 1987 to 1997. Sensitivity analyses were used to determine whether test sensitivity and specificity would affect cost thresholds. Costs for each strategy were then applied to actual practice patterns. The cost of modified care ranged from $158 to $228 for each followup visit when using a urinary marker with a sensitivity and specificity of 95% and 77%, respectively. The cost of standard care was $240 for each followup visit. Based on sensitivity analyses the probability of disease recurrence and urinary marker accuracy were important determinants of expected costs. Mean number of followup assessments for patients followed more than 3 years was 4.3, 2.2 and 1.5 for years 1, 2 and 3, respectively. Cumulative costs of modified care were lower than those of standard care. Urinary marker testing for followup of patients with superficial bladder cancer is less expensive than the standard method of cystoscopy and urinary cytology based on our model. Future studies will be required to consider other factors that could affect the cost advantage of urinary markers, including indirect costs, the psychosocial impact of testing and different surveillance frequencies.Keywords
This publication has 16 references indexed in Scilit:
- IMMUNOCYT 1 : A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACTJournal of Urology, 1999
- The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic indexBritish Journal of Urology, 1998
- Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumorsUrology, 1997
- Bard® BTA® Test Compared with Diagnosis of Recurrent Bladder CancerEuropean Urology, 1997
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996
- Factors affecting recurrence and progression in superficial bladder tumoursEuropean Journal of Cancer, 1995
- The Relationship Among Multiple Recurrences, Progression and Prognosis of Patients with Stages TA and T1 Transitional Cell Cancer of the Bladder Followed for at least 20 yearsJournal of Urology, 1995
- Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapyBMJ, 1994
- Morbidity Following Cystoscopy: Comparison of Flexible and Rigid TechniquesBritish Journal of Urology, 1990